4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-046732
Chief Executive Officer sold 15,416 shares at an average $2.57 ($39,664)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Brainard Diana · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-08-17 | Sale : show line 1 in the form 10b5-1 | −11,361 | $2.50 | $28,351 | 895,938 | D |
| 2023-08-18 | Sale : show line 2 in the form 10b5-1 | −4,055 | $2.79 | $11,313 | 891,883 | D |
| Open-market sales · 15,416 sh · avg $2.57 · $39,664 | ||||||
Loading xslF345X05/doc4.xml…